- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.12. | Moderna signs deal worth up to $503m with Nanexa | 37 | Pharmaceutical Technology | ||
| 11.12. | Moderna taps Nanexa to improve delivery of injectable therapies in back-loaded $500M pact | 19 | FierceBiotech | ||
| 10.12. | 59 NORTH COMMUNICATIONS: Nanexa and Moderna enter into license and option agreement for the development of PharmaShell-based products | 15 | Cision News | ||
| 10.12. | Nanexa AB: Nanexa and Moderna enter into license and option agreement for the development of PharmaShell-based products | 250 | GlobeNewswire (Europe) | The agreement covers the development of up to five undisclosed compounds. Nanexa will receive an upfront payment of USD 3 million and is entitled to up to USD 500 million in potential milestone payments... ► Artikel lesen | |
| 06.11. | Nanexa AB: Nanexa publishes interim report for January-September 2025 | 140 | GlobeNewswire (Europe) | We have progressed with the optimization of our GLP-1 formulations, extended an existing commercial partnership, received approval for a PharmaShell patent application in Japan and submitted three new... ► Artikel lesen | |
| 22.09. | Nanexa AB: Nanexa receives Japanese patent approval for specific PharmaShell structure | 427 | GlobeNewswire (Europe) | The approval strengthens Nanexa's patent portfolio, with additional patent applications filed in other strategically important countries
Nanexa announces that a key patent application has been granted... ► Artikel lesen | |
| 27.08. | Nanexa AB: Nanexa publishes interim report for January-June 2025 | 158 | GlobeNewswire (Europe) | The second quarter of 2025 has continued to validate our core belief at Nanexa that slow-release medicines can transform how we dose and therefore treat people living with a range of conditions. Reducing... ► Artikel lesen | |
| NANEXA Aktie jetzt für 0€ handeln | |||||
| 23.05. | Nanexa AB: All samples analyzed from the 30 mg dose group in the NEX-22 Phase I study | 347 | GlobeNewswire (Europe) | Nanexa announced today that all pharmacokinetic (PK) samples from the final dose group, 30 mg of the Phase I study for NEX-22, now have been analyzed. The results show increased exposure in line with... ► Artikel lesen | |
| 06.05. | Nanexa AB: Nanexa publishes interim report for January-March 2025 | 306 | GlobeNewswire (Europe) | Very interesting data from the latest study and successful share issue.
Significant events during the first quarter of 2025In January, Nanexa announced that the company had decided to carry out a directed... ► Artikel lesen | |
| 05.05. | Nanexa AB: Nanexa and Applied Materials terminates collaboration | 358 | GlobeNewswire (Europe) | Nanexa and Applied Materials, Inc. have collaborated since 2020 regarding production equipment to be used for upscaling of the PharmaShell process. The companies have now agreed to terminate the collaboration.
Through... ► Artikel lesen | |
| 05.05. | Nanexa AB: Analysis of the first samples from the 30 mg dose group in the NEX-22 Phase I study shows continued promising results | 186 | GlobeNewswire (Europe) | Nanexa announced today that the first pharmacokinetic (PK) samples from the final dose group, 30 mg, in the ongoing Phase I study for NEX-22 have been analyzed. The results show that the PK profile... ► Artikel lesen | |
| 07.04. | Nanexa AB: Continued Good Tolerability of NEX-22 at 30 mg Dose of Liraglutide in the NEX-22 Study | 164 | GlobeNewswire (Europe) | Nanexa AB announces that initial observations in the phase I study show that the 30 mg dose of NEX-22, a depot formulation of liraglutide, has been well tolerated by patients with type 2 diabetes who... ► Artikel lesen | |
| 25.03. | Nanexa AB: Nanexa doses the last patients with 30 mg liraglutide in the NEX-22-01 study | 628 | GlobeNewswire (Europe) | Nanexa announces that all patients have now been included in the fourth and final dose cohort in the Phase I study of NEX-22, a one-month formulation of liraglutide.
NEX-22 is a new promising treatment... ► Artikel lesen | |
| 12.03. | Nanexa AB: Nanexa doses first patient in the 30 mg dose group in the Phase I study with NEX-22 | 301 | GlobeNewswire (Europe) | Nanexa AB announces today that the first patient has been dosed in the 30 mg dose group in the ongoing Phase I study with NEX-22, the company's one-month formulation of liraglutide.
The ongoing Phase... ► Artikel lesen | |
| 19.02. | Nanexa AB: Nanexa publishes year-end report and Q4 report 2024 | 935 | GlobeNewswire (Europe) | The clinical Phase I study conducted in the NEX-22 project with good results and focus on the evaluation with Novo Nordisk has provided a good starting point for 2025.
Significant events during the... ► Artikel lesen | |
| 13.02. | Nanexa AB: Bulletin from Nanexa's Extraordinary General Meeting | 278 | GlobeNewswire (Europe) | The Extraordinary General Meeting (EGM) of Nanexa AB (publ) (the "Company") has been held on February 13, 2025, at which meeting submitted proposals were passed. The complete proposals for resolutions... ► Artikel lesen | |
| 28.01. | Nanexa AB: Nanexa expands Phase I study with NEX-22 with an additional dose group | 339 | GlobeNewswire (Europe) | Nanexa AB announces that the phase I study with NEX-22, the company's one-month formulation of liraglutide, will resume with further dose escalation with an expected start in the first quarter of 2025.... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| UNIVERSE PHARMACEUTICALS | 5,670 | +33,73 % | Universe Pharmaceuticals INC - 6-K, Report of foreign issuer | ||
| AQUESTIVE THERAPEUTICS | 5,965 | -0,17 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Broadens Patent Estate for Anaphylm | New patents extend protection for Anaphylm into 2037Anaphylm (dibutepinephrine) Sublingual Film, if approved by the FDA, will be the first and only oral medication for the rescue treatment of severe... ► Artikel lesen | |
| HARROW | 50,18 | -0,11 % | Harrow, Inc.: Harrow Health, Inc. Announces Closing of Acquisition of Melt Pharmaceuticals | NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the... ► Artikel lesen | |
| MILESTONE PHARMACEUTICALS | 2,030 | -2,17 % | Milestone Pharmaceuticals Inc.: Milestone Receives FDA Approval of CARDAMYST (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) | First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythmFDA approval in PSVT enables... ► Artikel lesen | |
| VYNE THERAPEUTICS | 0,560 | -2,17 % | VYNE Therapeutics: +167% für den NBC! | Kurz vor Weihnachten ist schon wieder Bescherung im No Brainer Club: VYNE Therapeutics liefert nach einem Top-Deal satte +167% Rendite innerhalb weniger Monate. Die Weihnachtsgeschenke der NBC-Mitglieder... ► Artikel lesen | |
| REVIVA PHARMACEUTICALS | 0,308 | 0,00 % | Reviva Pharmaceuticals: Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia | Written feedback from FDA pre-NDA meeting includes a recommendation to conduct a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for the... ► Artikel lesen | |
| INHIBIKASE THERAPEUTICS | 1,860 | +12,73 % | Inhibikase: H.C. Wainwright startet Coverage mit "Buy" und 385 % Kurspotenzial | ||
| BRIGHT MINDS BIOSCIENCES | 85,79 | +1,33 % | Cantor Fitzgerald bestätigt "Overweight" für Bright Minds Biosciences und sieht Potenzial in Hauptwirkstoff BMB-101 | ||
| LIPOCINE | 5,030 | +8,17 % | Lipocine Inc.: Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone | Second Drug Safety Monitoring Board (DSMB) meeting update planned for mid-January 2026
Topline results on track for the second quarter of 2026
SALT LAKE CITY... ► Artikel lesen | |
| LB PHARMACEUTICALS | 21,485 | -2,43 % | LB Pharmaceuticals Inc: LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer | NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 8,100 | +1,25 % | Kazia Therapeutics Limited: Kazia Therapeutics Regains Full Nasdaq Listing Compliance | Restoration of Nasdaq compliance follows $50 million institutional financing and reinforces balance-sheet strength
SYDNEY, Dec. 22, 2025 /PRNewswire/ -- Kazia Therapeutics... ► Artikel lesen | |
| FUNCTIONAL BRANDS | 0,236 | +4,85 % | Functional Brands Inc.: Functional Brands Inc. Launches Kirkman's(R) Skin, Beauty & Anti-Aging Bundle: A Science-Backed Approach to Radiant, Resilient Skin | Lake Oswego, Oregon--(Newsfile Corp. - December 22, 2025) - Functional Brands Inc. (NASDAQ: MEHA), a leading innovator in wellness and performance products, today announced the release of its Skin... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 2,690 | -4,95 % | Biodexa Pharmaceuticals PLC: Biodexa Announces Pricing of $10 Million Public Offering | December 18, 2025 Biodexa Announces Pricing of $10 Million Public Offering Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) ("Biodexa" or the "Company"), a clinical stage biopharmaceutical company developing... ► Artikel lesen | |
| MEDICUS PHARMA | 1,570 | +0,64 % | Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence Driven Clinical Data Analytics Platform | The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute urinary... ► Artikel lesen | |
| CITIUS PHARMACEUTICALS | 0,818 | +1,94 % | Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update | Subsidiary, Citius Oncology, launches cancer immunotherapy, LYMPHIR, in the U.S. in December 2025
CRANFORD, N.J., Dec. 23, 2025 /PRNewswire/ -- Citius Pharmaceuticals... ► Artikel lesen |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANEXA AB finden Sie auf Wallstreet Online.